Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : AstraZeneca
Deal Size : $2,085.0 million
Deal Type : Collaboration
Details : The collaboration aims to focus on the type 1 diabetes and inflammatory bowel disease using Quell’s proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock, to develop autologous multi-modular Treg cell thera...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $85.0 million
September 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : AstraZeneca
Deal Size : $2,085.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases
Details : The collaboration combines MiNA's expertise in the discovery & development of saRNA therapeutics with AstraZeneca's experience in bringing breakthrough treatments to patients with metabolic diseases.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
July 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration